FDA Approves Mitapivat for Anemia in Thalassemia Patients 
Moore Threads Unveils New GPUs, Fuels Optimism Around China’s AI Chip Ambitions 
Waymo Plans Safety and Emergency Response Upgrades After San Francisco Robotaxi Disruptions 
Saks Global Weighs Chapter 11 Bankruptcy Amid Debt Pressures and Luxury Retail Slowdown 
Boeing Wins $2.04B U.S. Air Force Contract for B-52 Engine Replacement Program 
FTC Praises Instacart for Ending AI Pricing Tests After $60M Settlement 
Texas App Store Age Verification Law Blocked by Federal Judge in First Amendment Ruling 
ByteDance Plans Massive AI Investment in 2026 to Close Gap With U.S. Tech Giants 
Niigata Set to Approve Restart of Japan’s Largest Nuclear Power Plant in Major Energy Shift 
Novo Nordisk Stock Surges After FDA Approves Wegovy Pill for Weight Loss 
Uber and Baidu Partner to Test Robotaxis in the UK, Marking a New Milestone for Autonomous Ride-Hailing 
Italy Fines Apple €98.6 Million Over App Store Dominance 
Mexico Antitrust Review of Viva Aerobus–Volaris Deal Signals Growth for Airline Sector 
Google and Apple Warn U.S. Visa Holders to Avoid International Travel Amid Lengthy Embassy Delays 
Roche CEO Warns US Drug Price Deals Could Raise Costs of New Medicines in Switzerland 
JPMorgan’s Top Large-Cap Pharma Stocks to Watch in 2026 
U.S. Lawmakers Urge Pentagon to Blacklist More Chinese Tech Firms Over Military Ties 
RALEIGH, N.C., April 18, 2016 -- PRA Health Sciences, Inc., (PRA) (NASDAQ:PRAH) is pleased to announce it was once again recognized as the Best Clinical Research Company of the Year. PRA received the award at the PharmaTimes Clinical Researcher of the Year Americas ceremony in Atlanta, Georgia. This is the second year in a row that PRA has received this prestigious recognition. In 2015 PRA was also named the Best International Clinical Company of the Year.
|
|||
A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/7401a9d9-079b-4ac0-9288-09a0f5b5c8d6
“This is an incredible honor for us,” said Michael Brooks, Executive Vice President, Product Registration, Americas. “PRA employees are passionate about their clinical development work and this award is recognition of their talent and dedication.”
PRA was well represented in the competition with 16 finalists in five different categories. Individual gold award recipients include:
- Experienced CRA: Raquel Amorim
- Strategic Partnership Team (PRA and CytRx): Stephanie Gonzalez, Sinead Pitts, Miriam Price
Organized by PharmaTimes, the Clinical Researcher of the Year competition is considered a key barometer of quality standards in the Clinical Research Organization (CRO) industry. The multi-stage competition is organized by an independent executive steering committee drawn from senior industry leaders from big and small pharma, leading CROs, and professional membership associations.
ABOUT PRA HEALTH SCIENCES
PRA is one of the world's leading global contract research organizations, by revenue, providing outsourced clinical development services to the biotechnology and pharmaceutical industries. PRA’s global clinical development platform includes approximately 70 offices across North America, Europe, Asia, Latin America, South Africa, Australia and the Middle East, and approximately 12,000 employees worldwide. Since 2000, PRA has performed approximately 3,300 clinical trials worldwide and has worked on more than 100 marketed drugs across several therapeutic areas. In addition, PRA has participated in the pivotal or supportive trials that led to U.S. Food and Drug Administration or international regulatory approval of more than 60 drugs. To learn more about PRA, please visit www.prahs.com.
MEDIA INQUIRIES: Christine Rogers, Manager - Public Relations, Corporate Communications EMAIL: [email protected] PHONE: +1 919.786.8463 INVESTOR INQUIRIES: [email protected]
